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ABSTRACT
Pancreatic cancer is nearly asymptomatic, which can result in extensive grow and even
metastasis to other organs before detection. When diagnosed at a late stage, the survival rate is
3%. Early detection is therefore the key to treating pancreatic cancer. Diabetes was identified as
a risk factor for the development of pancreatic cancer, but the mechanism remains unknown. In
this project, the objective was to delineate a link between diabetes and pancreatic cancer by
examining their shared protein signaling pathways. In a previous study, hyper-activation of
AKT1 resulted in a pre-diabetic phenotype and also increased upregulation of downstream
phosphorylated mTOR and phosphorylated p70S6 kinase. More recently, mice with mutations
that hyper-activated AKT1 and KRAS showed a significantly higher blood glucose level
compared to littermate matched wild-type, mutant AKT1, or mutant KRAS mice. Interestingly,
mice with a combination of mutations that hyper-activated AKT1 and KRAS also showed faster
development of pancreatic cancer compared to these other groups of littermate mice.
Toward determining a molecular basis for the crosstalk between AKT1 and KRAS,
pancreas and liver tissues were collected from all four groups of mice including wild-type,
mutant AKT1, mutant KRAS, and mice with dual AKT1/KRAS hyper-activation. One strategy
was to examine expression and/or phosphorylation of downstream protein signaling crosstalk by
analysis of p70S6K using Western Blots. Erk 1/2 proteins were also tested as downstream
proteins of KRAS to provide a molecular view of the individual and cooperative roles of AKT1
and KRAS in the mouse models. A potential feedback mechanism to affect insulin receptor
signaling in the pancreas was examined using enzyme-linked immunosorbent assays (ELISA). A
significant decrease in insulin receptor phosphorylation, possibly contributing to insulin
ii

resistance, was found when mice had mutant hyper-activated KRAS. Contrary to the original
expectations, mice with combined mutations of AKT1 and KRAS may contribute to the
accentuated diabetic phenotype by targeting two different points in the AKT and KRAS protein
signaling pathways. The information can help understand the relationship between glucose
metabolism, diabetes, and pancreatic cancer development. By thoroughly studying the
interactions between targets in the AKT1/KRAS signaling pathways, key molecular events that
induce metabolic changes and potentially early biomarkers may lead to an improved
understanding of risk and/or detection of pancreatic cancer.
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INTRODUCTION
Pancreatic Cancer Background
Pancreatic cancer is one of the most lethal cancers worldwide. It is the fourth-leading
cause of cancer deaths in 2016 for both males and females in the United States (Figure 1).
Patients suffered from pancreatic cancer have only 8% of overall 5-year relative survival rate,
which is the lowest among all major types of cancers. The American Cancer Society estimated
that over 40,000 of pancreatic cancer patients would die in 2017. This number of deaths is
approximately the same as the annual number of reported new cases.
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Figure 1. Estimated Cancer Deaths in 2017. (American Cancer Association, 2017)

The high mortality rate of pancreatic cancer is primarily due to the lack of a reliable early
detection method, since resection of the tumor during a local stage is the only effective cure
(Surgical Treatment of Pancreatic Cancer, 2016). Pancreatic cancer patients rarely display
distinctive symptoms in the early stage. Symptoms such as back pain, abdominal pain, and
jaundice are commonly observed in other diseases, which results in delayed diagnosis or even
misdiagnosis. Currently, cancer antigen 19-9 (CA 19-9) is the best available tumor marker but it
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cannot be used as a diagnostic or a screening test due to the suboptimal accuracy and specificity
(only 79-81% sensitivity) (Ballehaninna, 2011).
Consequently, the tumor remains unnoticed while continuing to grow and eventually
metastasizes to nearby organs, such as liver and small intestine. At this point, treatments like
surgery, chemotherapy, and radiation therapy are no longer effective. The 5-year relative survival
rate decreases substantially to 3% if the malignancy is detected in the advanced stage, which again
demonstrates the pressing need to develop a reliable diagnostic tool.

Types of Pancreatic Cancer
Pancreatic cancer has essentially uncontrolled cell growth due to genetic mutations that
accumulate in the tumors cells arising in the pancreas. The pancreas is an elongated and narrow Jshaped organ located behind the stomach and between the duodenum. It is anatomically divided
into the head, the body, and the tail of pancreas to function as both an endocrine and exocrine
gland, which could then lead to the formation of different pancreatic cancer. The diagnosis between
endocrine tumor and exocrine tumor is crucial to determine the risk factors and proper treatment
plan.

Pancreatic Neuroendocrine Tumors
Pancreatic neuroendocrine tumors (Islet cell tumors) are rarely occurring endocrine
pancreatic cancer (Kaur et al, 2012). The endocrine portion of the pancreas contains clusters of
hormone producing cells called the “islets of Langerhans”, which are small circular cells named
2

alpha cells and beta cells. These two cell types are essential in the regulation of glucose
homeostasis. Alpha cells secrete glucagon to elevate blood glucose levels by reducing the speed
of glycolysis and promoting gluconeogenesis. Beta cells produce insulin that increase cellular
intake of glucose and glycogen synthesis to lower blood glucose levels. The islet cell tumor (ICT)
is classified as “functional” if the neoplasm affects pancreatic hormone secretion and causes
hormonal deregulation symptoms, while it would be “nonfunctional” if the neoplasm has no
impact on the hormone secreting cells (Schwarz, 2009).

Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is the predominant form of pancreatic cancer and
the focus of this study. It is accountable for 94% of all reported cases in 2016 (American Cancer
Society, 2017). PDAC is originated from the exocrine portions that compose 85% of the pancreas.
Acinar cells in the exocrine pancreas produce digestive enzymes such as protease, lipase, and
amylase. The secreted pancreatic juice enters the duodenum through the pancreatic duct to aid in
digestion.

Current Treatments for Pancreatic Ductal Adenocarcinoma
Surgery
Although surgical resection is the only cure for PDAC, only 10-20% of patients are
eligible for the operation. In the American Joint Commission on Cancer (AJCC) staging system,
the surgically removable and localized tumors in these patients are considered to be in the
3

“resectable” stage (Katz et al., 2008). The rest of the patients are “borderline resectable” or
“unresectable” because the tumor had already locally advanced or metastasized due to the lack of
early detection method. However, 30% of patients may suffer from major complications after the
procedure, such as gastroparesis (partial paralysis of the stomach) and they could only live about
12-18 months longer than patients with an unresectable tumor (Chari, 2007).

Chemotherapy & Radiation Therapy
Chemotherapy is considered to be a supplementary treatment of PDAC. The length and
the type of treatment is based on the patients’ conditions, which can be given to patients before
or after the surgical resection to increase the success rate and survival rate (Pancreatic Cancer
Treatment, 2016). Anti-cancer drugs such as Gemcitabine raises the 1-year survival rate for
unresectable PDAC patients from 2% to 18%, and the survival rate can be further extended to
27% if coupled with Cisplatin (Heinemann, 2001).
Radiation therapy is sometimes used along with chemotherapy to support the treatment.
This treatment can be given to “borderline resectable” tumor in order to shrink the tumor. It can
also be given after surgery to lower the chance of recurrence. However, the effect of this therapy
is still uncertain because it could have positive or negative overall outcome on different patients.
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Molecular Basis for Pancreatic Ductal Adenocarcinoma Development
PDAC arises from the epithelial cell of the pancreatic duct. Pancreatic intraepithelial
neoplasia (PanIN) is the precursor lesions of PDAC that is classified from PanIN-1 to PanIN-3
based on the structural and nuclear distortion. PanIN-1 is subdivided into flat epithelial lesion
(PanIN-1A) and papillary epithelial lesion (PanIN-1B). PanIN-2 lesion begin to display nuclear
abnormality such as some loss of polarity and enlarged nuclei. PanIN-3 is papillary with complete
loss of nuclear polarity (Klein et al., 2002). It would take approximately 17 years to fully develop
from PanIN-1 lesion into an invasive PDAC. The symptoms are likely to appear after PDAC
reaches regional or distant stages. Patients may suffer from abdominal pain, back pain, weight loss,
jaundice, and gallbladder or liver enlargement (Stark & Eibl, 2015).

KRAS
Epidemiological studies point to several risk factors that lead to PDAC progression. Certain
genetic mutations are associated with the development of PDAC, such as KRAS, BRCA-1 &
BRCA-2, and CDKN2A. Specifically, the KRAS oncogene is present in 99% of PanIN-1 and 95%
of PDAC (Makohon-Moore & Iacobuzio-Donahue, 2016). KRAS is a 21 kDa GTP-binding protein
that mediates cell growth by cycling through the active GTP-bound and inactive GDP-bound states
(Cox et al. 2015). The mutation of KRAS gene leads to the formation of constitutively active GTPbound KRAS and uncontrolled cell proliferation, which serve as an important PDAC initiation
factor. KRAS also plays a role in inducing a chronic inflammation environment associated with
PDAC (Liu et al., 2016).
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Chronic Inflammation
Patients who suffer from chronic inflammatory diseases such as pancreatitis are also
susceptible to PDAC development. These patients have higher chance of experiencing undesirable
mutations because of the constant cycle of damage and repair in the pancreas. Smoking cigarette
can cause DNA damage by ingesting carcinogens and obesity induce a pro-inflammatory state that
favors genetic mutation. Although PDAC generally arise spontaneously, about 2% of the cases are
hereditary (Windsor, 2007). Mutations in germline variant the that maintains genomic stability,
such as BRCA 1 and BRCA 2, would increase the rate of mutations in cells during homologues
recombination or DNA double-strand break repair machinery. The incidence and death rate of
PDAC increase with aging since pancreas lesion persist for a long time (American Cancer Society,
2017). The accumulation of intrinsic mutations over the years in both oncogene and tumor
suppressor genes along with extrinsic factor like smoking, would eventually drives the tumor to
an exponential growth phase.

Diabetes
The progression of PDAC continues once the mutated cells are fixed in the epithelial cell
population after passing through the surveillance of apoptosis, senescence, and immunoresponse.
According to prior epidemiology studies, two-thirds of the PDAC patients are diabetic or glucose
intolerant and 75% of the cases are recent onset diabetes (Munira & Chari, 2012). The increase in
glucose uptake or glucose accumulation correlates with more rapid tumor progression as well as
reduced response to treatments. Diabetic phenotypes could arise before or after PDAC formation.
The cause and effect conundrum makes it difficult to sort out the relationship between the
6

morbidities. The Warburg effect suggests that cancer cells favor aerobic glycolysis instead of
oxidative phosphorylation which is used in normal cells (Vander Heiden, 2009). Although aerobic
glycolysis is not as efficient in ATP production, this process conserves carbon sources to produce
biomass that is essential for cancer cells to rapidly proliferate. As such, glycolytic enzymes were
found strongly increased in pancreatic tumor cells compared with normal pancreatic cells (Blum
& Kloog, 2014).
In type II diabetes patients, their blood glucose accumulates and generates a hyperglycemic
environment that cancer cells thrive in. The regulation of blood glucose is highly dependent on
glucagon and insulin secreted by the endocrine pancreas to interconvert between glucose and
glycogen. Although normal insulin secretion is observed in type II diabetes patients, their cells are
resistant to insulin which fail to respond to the hormonal regulation (Classification and Diagnosis
of Diabetes, 2015). Insulin resistance of the cell leads to hyperinsulinemia and hyperglycemia,
which are both associated with an increased risk of PDAC despite of obesity (Cui & Anderson,
2012) (Stattin et al., 2007).

AKT
AKT, also known as protein kinase B, has 3 highly conserved isoforms (AKT1, AKT2, and
AKT 3) that regulate cell growth and proliferation. The isoform AKT2 is known to play a critical
role in glucose metabolism through insulin mediation since AKT2 knock-out mice are glucose
intolerant and insulin resistant. Recent study has shown that AKT1 regulate glucose metabolism
through glucagon instead, whereas the AKT1 mice remain sensitive to insulin stimulation (Albury
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et al., 2016). Hyper-activated AKT1 mice exhibit a pre-diabetic phenotype that can be turn on and
off by doxycycline treatment and is often found activated in PDAC tumor.
Remarkably, the combination of hyper-activated AKT1 and KRAS leads to a more severe
diabetic phenotype and faster PDAC development compared to other groups of mice (Albury et
al., 2015). We hypothesize that the crosstalk between AKT1 and KRAS upregulates the production
of downstream proteins in the corresponding protein signaling cascades (Figure 2). One potential
method to delineate the mechanism is to examine cells’ protein signaling pathway, which is often
considered as the language of cells.

Figure 2. AKT and KRAS Signaling Pathway
Insulin receptor substrate 1 (IRS-1), phosphatidylinositol 3-kinase (PI3K), phosphatidylinositol 3,4,5-trisphosphate
(PIP3), 3-phosphoinositide-dependent protein kinase-1 (PDK1), AKT1, mammalian target of rapamycin complex 1
(mTORC1), KRAS, Rapidly Accelerated Fibrosarcoma (RAF), MEK, Extracellular signal-regulated kinase (ERK)
1/2, p90 ribosomal protein S6 kinase (RSK), ribosomal protein S6 kinase beta-1 (p70s6K).
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Study Design
In the study of PDAC, the KRAS gene is being investigated because of its essential role for
cancer development observed in PanIN-1 and PDAC tumors. In addition, the AKT1 gene alone has
the effect of generating a pre-diabetic phenotype in mice while speeding up the PDAC
development if coupled with constitutively activated KRAS. To study the link between diabetes
and PDAC, wildtype, AKT1, KRAS, and AKT1/KRAS mice groups were selected in this project.
The AKT1 transgenic mice are used to mimic diabetic patients because of its function in glucose
metabolism. This also provides a more controlled model since the AKT1 mice generally acquire
diabetes before tumor development, and it progresses with advanced age. The KRAS transgenic
mice are used to mimic PDAC patients since it is a prevalent oncogene in PDAC patients.
We will focus on a junction protein, p70S6K, to validate the crosstalk between AKT1 and
KRAS using western blots. Another protein of interest, ERK1/2, is also examined to determine the
expression of KRAS under the crosstalk effect. Additonally, enzyme-linked immunosorbent assay
(ELISA) is used to study membrane receptors that initiate the pathways by binding with total and
phosphorylated insulin receptors. This could potentially reveal the mechanism of diabetes and
PDAC development in AKT1/KRAS mice. The study of convergent points in the pathways of
AKT1 and KRAS could potentially lead to a greater understanding of the relationship of glucose
metabolism and the progression of pancreatic cancer.
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MATERIALS AND METHODS
Genetically Engineered Mice
The animal studies were in compliance with the UCF Institutional Animal Care and Use
Committee at the Association for Assessment and Accreditation of Laboratory Animal Care
International accredited(AAALAC) UCF Lake Nona Animal Facility. Mice with TetOMyrAKT1, but lacking the knock-in Pdx-tTA, were classified as normal or wild-type litter
mates. Mice with Pdx-tTA and TetO-MyrAKT1 were classified as AKT1Myr mice having
constitutively active AKT1 in the pancreas. Mice with Pdx-Cre; LSL-KKRASG12D were
classified as KKRASG12D. Mice with Pdx-tTA, TetO-MyrAKT1, and Pdx-Cre; LSLKKRASG12D were classified as AKT1Myr/KKRASG12D. All mice were euthanized according
to American Veterinary Medical Association guidelines.

Blood Glucose Measurement
At least 6 individuals from each group of ~5 month old mice (WT, Akt1, KKRAS, and
Akt1/KKRAS) were tested for blood glucose using a Contour glucometer (Bayer, Mississauga,
Ontario, Canada) at 20 weeks.

Protein Homogenize
17 mice from the various groups were euthanized after fasting overnight and then blood and
various tissues, including pancreas and liver, were collected and frozen. Tissue samples were
homogenized mechanically using tubes with pestles (Kimble Biomasher II) in Tissue PELB (G10

Biosciences) and Protease & Phosphatase Inhibitor (Pierce). Another set of pancreas samples
were homogenized mechanically in liquid nitrogen using ceramic mortar and pestle in RIPA
Buffer (Santa Cruz) and Protease & Phosphatase Inhibitor (Pierce). The supernatants were
collected after centrifugation at 20,000 g for 15 minutes at 4°C and the pellets were disposed.
The concentrations of the extracted total proteins were determined using Coomassie Assay
compared to a known reference protein, Bovine serum albumin (BSA).

Western Blots
For western blot analysis, 60 μg of each protein extract was combined with 4x Laemmli Sample
Buffer and denatured in a boiling water bath for 5 minutes. Chameleon Duo Pre-Stained Protein
Ladder (LI-COR) and protein samples were separated on 4% sodium dodecyl sulfate stacking gel
and 12% sodium dodecyl sulfate resolving gels using a Mini-Protean Tetra Cell (Bio-Rad) unit.
The gel was running at 80V for 15 minutes and then 100V for 1 hour. Proteins were transferred
to immobilon-P PVDF Transfer Membrane (Millipore) at 100V at 4°C for 1 hour and 30 minutes
using a Mini-Protean Tetra Cell (Bio-Rad) unit. Antibodies for western blots were anti-Totalp70S6K, anti-Phospho-p70S6K, anti-Phospho-ERK1/2, and anti-Beta-Actin antibodies (all from
Cell Signaling Technology). Secondary antibodies were anti-mouse (DyLight, Thermo) and antirabbit (IR Dye; LI-COR Biosciences, Lincoln, NE), and signals were visualized using an
Odyssey Infrared Imaging System (LI-COR).

11

ELISA
Four solid phase sandwich ELISA kits (all from Invitrogen): AKT (Total), AKT (pS473), Insulin
Receptor (Beta-subunit), and Insulin Receptor (pY1158) were used.
The samples and the specific standard provided by the ELISA kit were added to the antibodycoated wells for 2 hours of incubation at 25°C. Detection antibody was added after 4 washing
steps and incubate for 1 hour at 25°C. After washing steps, secondary antibody (streptavidinHRP) was added to the wells for 30 minutes of incubation. After washing and 30 minutes of
incubation with stabilized chromogen, stop solution was added and the absorbance was read at
450 nm.
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RESULTS
At 20 weeks, WT, AKT1, KRAS, and AKT1/KRAS mice (n=30) blood glucoses were
tested in by a glucometer. A portion of AKT1/KRAS mice (n=3) have significantly higher nonfasting blood glucose levels (600+ mg/dl) than the wild-type, AKT1, and KRAS mice. The rest
of the AKT1/KRAS mice (n=8) have non-fasting blood glucose levels similar to AKT1 mice
(Figure 3 & 4).
The level of activities of AKT and insulin receptor is determined by running ELISAs.
AKT (Total), phosphorylated AKT(pS473), and insulin receptor (β - subunit) demonstrated
persistent level of activity across the board (Figure 5, 6, and 7). However, there is a substantial
variance among AKT1 and KRAS mice in the level of the phosphorylated insulin receptor
(pY1158) (Figure 8).
Western blot analysis shows inconsistent bands of p70S6K (70 kDa) for the tissue
samples extracted with the Tissue PELB. The image has strong background noise for all four
groups of mice on the 12% SDS-Gel (Figure 9) and unknown heavy bands are observed
universally at the top of the gel. After switching from PELB to the standard RIPA buffer, the
result for ERK1/2 (44/42 kDa) bands are consistent but the strength of the signal is not ideal
(Figure 10). The control, Beta-actin (43 kDa) bands, are shown in the gel with unknown heavy
bands at the top of the gel again (Figure 11).
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Figure 3. Non-fasting Blood Glucose Level in 6 months old Mice
Blood glucose levels were measured in 6 months old mice using a glucometer. AKT1/KRAS** mice are found to
have blood glucose level higher than 500 mg/dL. This group of mice have a more severe diabetic phenotype
compared to AKT1 and are suspected to be at risk of PDAC development.
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Figure 4. Total Concentration Determination using Bradford Coomassie Assay
A known reference protein, Bovine serum albumin (BSA), was used during the Coomassie Assay to determine the
total concentrations of the protein.
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Figure 5. ELISA Assay for Total AKT
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Figure 6. ELISA Assay for AKT (pS473)
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Figure 7. ELISA for Insulin Receptor (β - subunit)
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Figure 8. ELISA for Insulin Receptor (pY1158)
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A/R (High)
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Figure 9. 12% SDS- PAGE, anti-Total and anti-Phospho p70S6K
Results of western blot analyses of p70S6K (70 kDa) in homogenized pancreas and liver tissues from mice 5790
(Wild-type), 5767 (AKT1), 5792 (KRAS), 5778 (AKT1/KRAS). p70S6K is detected using 12% gel and anti-Total and
anti-Phospho p70S6K. Unknown heavy bands are also found at the top of the gel.
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Figure 10. 12% SDS- PAGE, anti-ERK1/2
Results of western blot analyses of ERK1/2 (44/42 kDa) in homogenized pancreas and liver tissues from mice 5790
(Wild-type), 5767 (AKT1), 5792 (KRAS), 5778 (AKT1/KRAS). Erk1/2 is detected using 12% gel and anti-ERK1/2.
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Figure 11. 12% SDS- PAGE, anti-Beta-actin
Results of western blot analyses of Beta-actin (43kDa) in homogenized pancreas and liver tissues from mice 5790
(Wild-type), 5767 (AKT1), 5792 (KRAS), 5778 (AKT1/KRAS). Beta-actin (43 kDa) is detected using 12% gel and
anti-B-actin. Unknown heavy bands are also found at the top of the gel.
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DISCUSSION
PDAC is the fourth leading cause of cancer death in the United States. Diabetes has been
shown to be a risk factor for the development of this deadly malignancy. This project aims to
investigate the mechanism of the deregulated glucose metabolism at the molecular level. In this
experiment, the wild type mice had an average glucose level of 128.1 mg/dl. The non-fasting
blood glucose test demonstrated the severe glucose deregulation in the 20 weeks old transgenic
AKT1/KRAS mice, which can be further divided into a high glucose level group (600+ mg/dl)
and a relatively low glucose level group (174.75 mg/dl).
The high glucose level group is suspected to be at risk of PDAC development. PDAC is
an age-related malignancy that takes 17 years in human to be fully established from panIN-1.
Therefore, the low glucose level group of AKT1/KRAS is expected to progress into more
deregulated blood glucose levels and eventually merge with the high glucose level group.
Total and phosphorylation specific sites of AKT and insulin receptor are an indication of
the molecular response to the genetic mutation that could lead to sequential molecular activities.
The total AKT ELISA demonstrated the effect of the transgenic myristoylated AKT as the mice
with mutant AKT mice have a significantly higher concentration (644.1 ng/mL) compare to the
wildtype mice (484.8 ng/mL) in the pancreas. The serine phosphorylation at amino acid number
473 is one of two sites that need to be phosphorylated for full activity of the AKT protein kinase.
However, the level of activities of phosphorylated AKT at serine residue 473 in AKT1/KRAS
mice is remain persistent across all 4 genotypes. AKT activation is stimulated by growth factors
and hormones such as insulin at the upstream receptor. The endogenous AKT activation is more
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dependent on those stimulations rather than genetic modification, which shows that hyperactivation of AKT1 is not the sole contributor to the amplified glucose deregulation.
On the other hand, the KRAS mice have a substantial variance in the level of Insulin
Receptor at the one of the three phosphorylation sites, namely tyrosine residue 1158 (Y1158), in
the pancreas. This site is known to be functionally important to the autophosphorylation of the
two intracellular beta-subunits of the insulin receptor and acts as a stabilizer (Hubbard, 2013). A
reduced phosphorylation of the Y1158 site will decrease the kinase activity of the insulin
receptor. This finding can be related to the insulin resistance displayed in the KRAS mice that
contribute to further deregulate the glucose metabolism. There may be an outside pathway of
KRAS that directly/indirectly represses the phosphorylation of the insulin receptor, which work
independently from the AKT signaling pathway. We will conduct ELISAs again with a larger
sample size of KRAS mice to confirm this finding.
In the meantime, we have yet to identify the crosstalk effect between the AKT and KRAS
pathway. The initial attempt to homogenize the mice tissues using tubes with pestles (Kimble
Biomasher II) in Tissue PELB (G-Biosciences) was unsuccessful. We intended to use a milder
detergent to minimize the damage and preserve the structures of the protein of interest during
homogenization. However, the plastic pestles did not provide enough rigidity to grind the
samples into the appropriate form. The Tissue PELB used was also not strong enough to fully
lyse and extract the protein from the mammalian cells. We believe that certain amount of protein
remained in the insoluble protein pellet and was disposed after centrifugation, whereas the lysate
contained cells that has not been completely lysed. To continue with the project, we decided to
switch to the ceramic mortar and pestle to have a stronger grinding force. Tissues were frozen in
21

liquid nitrogen during the homogenization to prevent degradation. We also used the standard
RIPA buffer to ensure the cells lyse completely. The unknown heavy bands found at the top of
the 12% SDS-Gel were the result of the expiration of the 2-mercaptoethanol the Laemmli's
loading buffer to fully denature the protein samples, which was easily solved by adding fresh 2mercaptoethnol in the loading buffer.
In this study, we demonstrated the severe deregulation of glucose metabolism in
AKT1/KRAS mice could be the result of the independent action of AKT1 and KRAS pathways.
Although the hyper-activated AKT1 mice has shown to have elevated blood glucose level and
establishment of a diabetic phenotype, it is not the only contributor to the severely deregulated
AKT1/KRAS mice group.
AKT1 and KRAS pathways may have different unique mechanisms to affect the blood
glucose levels. The AKT1 hyper-activation mutation leads to excess secretion of glucagon,
which results in the breakdown of glycogen to elevate blood glucose level. Insulin is less
effective at activating insulin receptor through mutant hyper-active KRAS due to the insufficient
phosphorylation at site Y1158. These cells are found to be insensitive to glucose uptake in
KRAS mice and blood glucose level continues to elevate.
Activated KRAS may contribute to the metabolic reprogramming of the cells and
pathways such as glucose transport. RRAD (Ras-Related Associated with Diabetes) is a small
GTPase that is associated with type II diabetes. Recent studies have suggested that RRAD acts as
tumor suppressor by inhibiting the expression of glucose transporters (Wang et al., 2014).
Inactivation of RRAD by DNA methylation is commonly seen in tumor tissues, which increases
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glucose uptake in tumor cells, which subsequently perform aerobic glycolysis known as the
Warburg effect (Yan et al., 2016).
In conclusion, the findings of this study suggest that the combined effect of glucagon
mediated prediabetic phenotype and the insulin resistance contributes to the severely deregulated
blood glucose level in AKT1/KRAS mice (Figure 12). The phosphorylated insulin receptor
ELISA would need to be replicated with greater sample size to confirm this finding. The search
for the crosstalk effect between the pathways continues, as we have optimized the protein
homogenization method for mouse pancreas tissue. The expression level of the p70S6K also
could be examined more thoroughly as a mechanism to indirectly lead to the inhibition of the
glucose transporter type 4 (GLUT 4) that essentially contributes to the glucose uptake.
Collectively, the study of the interaction of AKT1 and KRAS signaling pathways could lead to a
greater understanding of the linkage between diabetes and PDAC, as well as potential markers
for early detection of PDAC.

AKT1

KRAS

↑ Blood glucose by
excess glucagon
secreation

↓ Glucose transport

↑↑↑
Blood Glucose Level
in AKT1/KRAS mice

due to insulin
resistance

Figure 12. Model of AKT1 and KRAS combined effect on glucose deregulation.
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